Preventing AKI

Developing the first ever drugs to prevent acute kidney injury (AKI).

Inflammation related AKI

International Phase II trial with LSALT peptide to prevent acute kidney injury (AKI).

Targeting Toxin Related AKI

Cilastatin is a major commercial drug candidate suited to preventing acute kidney injury (AKI).

Investor Relations

Stock information, press releases, financials and management’s discussion and analysis.

The Company

Find out about Arch Biopartners’ approach and meet the team behind our science.

Novel drugs to prevent acute kidney injury

Arch is a late-stage clinical company aggressively pursuing the development of acute kidney injury (AKI) treatments as its primary endpoint for commercializing its two lead drug candidates.

Together, LSALT peptide (Phase II ongoing) and Cilastatin (repurposed) have the potential to significantly improve outcomes for up to 60% of patients at risk of AKI – a debilitating condition and critical unmet medical need affecting more than ten million people annually in the US and Europe.

Organ inflammation, a common driver of injury and disease, currently has no effective treatments available on the market. AKI represents an ideal initial focus for Arch’s lead drug candidates, as success in this area could pave the way for broader applications, including lung and liver inflammation, other AKI indications, and septic shock.

A global leader in developing peptides, antibodies, and small molecules to address organ inflammation, Arch is advancing a therapeutic platform targeting key pathways involved in inflammation, including the enzyme dipeptidase-1 (DPEP1). Led by LSALT peptide, which targets the DPEP1 pathway, the platform also includes Cilastatin, a drug with potential applications in reducing kidney inflammation caused by toxins.

Arch Biopartners Approach

The company has a long history of working closely with the scientific community, universities and research institutions. Arch Biopartners mission is to advance and build the value of select therapeutic innovations, develop the most promising intellectual property, and create value for its investors.

Find out more about the Company, our focus and the fundamentals that make Arch unique.

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With this ethics approval in place and all training and preparations complete, the clinical team at Toronto General Hospital (TGH) is now ...

Full Release

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed a non-brokered private placement offering of 145,000 common shares priced at CAD $1.55 per common share and 90,000 common shares priced at USD $1.15 (the “Common Shares”) for total gross proceeds of CAD $374,000 (the “Offering”). The final amount of the Offering was an increase of CAD $24,000 from the amount originally disclosed to the market on March 5, ...

Full Release

Find out about the company’s recent advancements, new patents, corporate filings, information for investors and all progress updates on active clinical trials.

Browse all of the company’s material news releases.
Read the latest releases when they are published here or via email by subscribing to email alerts and news.

Arch Biopartners key stock indicators.

The Stock Performance page displays current and historical data for both of the Arch Biopartners symbols on the TSX Venture Exchange in Canada (ARCH.V) and the OTCQB Venture Exchange (ACHFF) in the USA.

Please be sure to subscribe for email updates when the company issues news releases and to receive announcements of new scientific data and company events and presentations.

The company’s reports and filings include current filings and an archive for investors and the public to use for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR+ website here .

Investor Information

Stock data, insights, filings, latest news.

Subscribe for email updates

Get email alerts when news is published

Latest Scientific Publications

Arch Biopartners science team’s published findings and articles in peer-reviewed journals.

Lead drugs, scientists, publications & trials

LSALT peptide, is the company’s lead drug candidate targeting acute kidney injury and other organ inflammation injuries in the kidneys, lungs and liver.

LSALT peptide trials and development

The company is the sponsor of a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). Drug approval for treating this type of inflammation related kidney injury may enable off-label use for other indications such as lung or liver inflammation injury, other AKI indications and septic shock.

LSALT peptide was shown to prevent inflammation in pre-clinical models of AKI, similar to the inflammation found in CS-AKI

Click to WATCH LSALT peptide At work

Video data behind Arch lead scientists publication in Cell shows the real-time effects of LSALT peptide when used to prevent inflammation in pre-clinical models of AKI, similar to the inflammation found in CS-AKI – click to watch the videos and learn more about LSALT peptide.

The CS-AKI trial began dosing patients in March 2024. Starting with five hospital sites in Turkey, one active site in Calgary and two additional sites announced in Toronto (pending activation). The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.

November 2024, announcement of dosing of the first patient dosed at the University of Calgary, Cumming School of Medicine, the first Canadian site to join and activate in the trial.
April 2024, announcement of St Michael’s Hospital and Toronto General Hospital (UHN) joining the trial.
March 2024, dosing of first patient in Turkey marking the commencement of the Phase II CS-AKI trial.
March 2024, publication of previous Phase II trial results targeting DPEP1 mediated lung inflammation provides further scientific rationale to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation injury for other indications.

Find out more about our science platforms and about LSALT peptide clinical trials and development targeting the treatment and prevention of common injuries and diseases related to organ inflammation.

Cilastatin is Arch’s second drug asset targeting acute kidney injury (AKI)

a DPEP1 inhibitor suited to preventing AKI caused by toxins

In 2024, the company announced that it is repurposing cilastatin and working with research and clinical collaborators to develop the drug as a new treatment to prevent toxin-related AKI.

Cilastatin was originally developed in the early 1980s by Merck Sharp & Dohme Research Laboratories to limit DPEP1’s role in the breakdown of imipenem, a β-lactam antibiotic used for the treatment of systemic infections. Now off patent, Arch is producing cilastatin to be approved for the first time as a standalone drug product.

Arch has method-of-use patents for cilastatin as a treatment to prevent kidney injury – currently issued or pending
Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissue
In August 2024, Arch announced that the company is participating in the PONTiAK phase II trial targeting acute kidney injury caused by drug toxins

AKI reflects a broad spectrum of clinical presentations ranging from mild injury to severe injury that may result in permanent and complete loss of renal function. Clinically, the causes of AKI include sepsis, ischemia-reperfusion injury, and various endogenous as well as exogenous (drug) toxins. There is no specific therapeutic treatment available in the market today that prevents AKI. In the worst cases, the kidneys fail, requiring dialysis or kidney transplantation for patient survival.

Patents for imipenem and cilastatin have expired and the combination drug is currently in a generic phase. There is no commercial history of cilastatin as a stand-alone drug product.

An experienced group of scientists working together to develop the Arch science platforms.

Science and Research Teams

Current work on LSALT peptide and Cilastatin is directed by Arch’s larger Treatments for Inflammation Team, led by Dr. Daniel Muruve (Arch Biopartners CSO), Dr. Justin Macdonald Ph. D., and Dr. Arthur Lau Ph. D (Arch Biopartners Project Director), who are primarily based at the University of Calgary. David Luke, BScPhm, PharmD, is a Strategic Advisor and Senior Clinical Lead working to support the Board of Directors and the company’s ongoing clinical trials with LSALT peptide.
The DPEP1 Inflammation Pathway and LSALT Peptide (Metablok) were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D., Jennifer Rahn B Sc., M Sc. and their colleague Dr. Paul Kubes at the University of Calgary.

The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.

Treatments for Inflammation publications surrounding the development of LSALT Peptide as a treatment for inflammation with broad application to prevent organ and tissue injury
BMJ Open, March 2024 – Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)
Science Advances, February 2022 – Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury
Cell, August 2019 – Dipeptidase-1 is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver